# Two Major 2026 Reviews Went Looking for Cannabis Trials in Depression. One Found None at All. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-for-depression-evidence-gap/ > **Published:** 2026-09-13T10:53:25-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:38:57-04:00 > **Clinical Summary:** Two 2026 meta-analyses found no randomized evidence that cannabis for depression works as a primary treatment. What that gap means for patients. --- CED Clinical Relevance #84Strong Clinical RelevanceDepression is among the most common reasons patients tell us they use cannabis, and it is the one psychiatric indication where the randomized evidence is effectively empty. Knowing that precisely changes how the conversation should go. Two large systematic reviews published in 2026 searched forty-five years of the psychiatric literature. Between them they screened thousands of studies and pooled hundreds. On depression, the condition patients ask about most, one review found no qualifying randomized trial at all and the other found a pooled effect indistinguishable from zero. Clinical Insight | CED Clinic The Wilson meta-analysis in *The Lancet Psychiatry* set out to test cannabinoids as the primary treatment for diagnosed mental disorders. Across 54 randomized trials and 2,477 participants, it reported an outright absence of randomized trial evidence for the treatment of depression. A second 2026 review, by Bharat and colleagues in *Psychiatry Research*, cast a wider net and did pool depression data. Its result was a standardised mean difference of -0.20 (95% CI -0.43 to 0.04), which the authors describe as trivial to no effect, drawn largely from depression scores measured as secondary outcomes in trials run for other conditions. Cannabis and DepressionMental Health EvidenceClinical ResearchEvidence InterpretationPatient Counseling AudiencePatients, caregivers, and cliniciansPrimary TopicRandomized trial evidence for cannabinoids in depressionSource[Read the full source](https://doi.org/10.1016/S2215-0366(26)00015-5) Why This Matters Depression is one of the most frequently cited reasons people give for using cannabis, and one of the most frequently listed qualifying conditions in state programs that allow provider discretion. The evidence supporting that practice is not weak. On the specific question of cannabis as a treatment for a depressive disorder, it is close to nonexistent. That distinction matters at the bedside. A clinician who says the evidence is mixed is describing a different situation from one who says the trials were never run. The second statement is accurate, and it leads to a more honest conversation about what a patient is and is not signing up for. What These Two Reviews Were Actually Asking Jack Wilson and colleagues at the Matilda Centre, University of Sydney, published their systematic review in *The Lancet Psychiatry* in the April 2026 issue, with online publication on March 16, 2026. They searched Ovid MEDLINE, PsycINFO, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and Embase for peer-reviewed randomized trials published between January 1, 1980 and May 13, 2025. The inclusion criterion was narrow and deliberate: the cannabinoid had to be tested as the primary treatment for the mental disorder or substance use disorder in question. Fifty-four trials met that bar, covering 2,477 participants. None of them studied depression. The authors state it plainly in their findings: there was an absence of randomized controlled trial evidence for the treatment of depression. Chrianna Bharat and colleagues at the National Drug and Alcohol Research Centre, UNSW Sydney, took a broader approach in *Psychiatry Research*, published August 11, 2026. They included 82 experimental and 118 observational studies and allowed symptom-level outcomes rather than requiring the disorder to be the trial’s primary indication. That wider frame did produce pooled depression data, and the pooled result was a standardised mean difference of -0.20 with a confidence interval crossing zero. A Pooled Effect That Crosses Zero Is Not a Positive Finding The Bharat depression estimate deserves a careful read rather than a headline. A standardised mean difference of -0.20 sits at the boundary of what is conventionally called a small effect, and the 95% confidence interval runs from -0.43 to 0.04. An interval that includes zero means the data are compatible with no benefit. Heterogeneity was extreme at I-squared 91.6%, meaning the individual studies disagreed with each other far more than chance would predict. The authors also flag where those depression scores came from. Much of the anxiety and depression evidence, they write, was measured as secondary outcomes in trials whose primary condition was something else entirely, such as chronic pain or multiple sclerosis. A depression scale administered to a pain trial population is not the same instrument, in the same hands, as a depression scale administered to people recruited for a depressive disorder. Overall certainty across the Bharat review was rated predominantly very low. That is the lowest rung on the GRADE ladder, and it means the true effect could be substantially different from the estimate. This Is Not a New Gap. It Is a Persistent One. Seven years earlier, Nicola Black and colleagues published a systematic review in the same journal, *The Lancet Psychiatry*, in December 2019. They searched the literature from January 1980 to April 2018 and included 83 studies, 40 of them randomized trials covering 3,067 participants. Forty-two of those studies addressed depression, including 23 randomized trials with 2,551 participants, yet the trials were overwhelmingly conducted in people with other primary medical conditions. Black and colleagues concluded that there was scarce evidence to suggest cannabinoids improve depressive disorders and symptoms. The 2026 reviews, working with a literature that grew for another seven years, reached the same place. One found nothing qualifying at all under a stricter definition, the other found a pooled estimate compatible with no effect. Three review teams, three search strategies, three publication dates spread across seven years, and one consistent answer. These groups overlap in membership, which is worth naming, but the consistency across changing inclusion rules is itself a finding. Where the Same Reviews Did Find Signal The Wilson review was not uniformly negative, and reading it as a blanket verdict on cannabinoids misses its structure. A combination of cannabidiol and delta-9-tetrahydrocannabinol reduced cannabis withdrawal symptoms (SMD -0.29, 95% CI -0.57 to -0.02) and weekly grams of cannabis used (SMD -1.00, 95% CI -1.69 to -0.30) in people with cannabis use disorder. It reduced tic severity in tic or Tourette’s syndrome (SMD -0.68, 95% CI -1.03 to -0.34). Any cannabinoid type increased sleep time in people with insomnia, measured both by electronic device (SMD 0.54, 95% CI 0.14 to 0.95) and sleep diary (SMD 0.55, 95% CI 0.01 to 1.09). Autistic traits decreased in autism spectrum disorder (SMD -0.36, 95% CI -0.66 to -0.07). The pattern is worth noting. Where cannabinoids showed measurable effects, the targets were physical or behavioral and reasonably objective: tics, sleep duration, grams consumed. The conditions where the evidence went quiet were the ones defined by internal mood state. The Safety Column Is Not Blank Both 2026 reviews found a consistent tolerability signal. Wilson and colleagues reported higher odds of all-cause adverse events with cannabinoids compared with control (OR 1.75, 95% CI 1.25 to 2.46), with a number needed to treat to harm of 7, and no higher odds of serious adverse events or study withdrawal. Bharat and colleagues found the single significant safety result to be increased withdrawals due to adverse events with THC (OR 2.78, 95% CI 1.66 to 4.65). Wilson and colleagues also reported that cannabinoids increased cocaine craving in people with cocaine use disorder (SMD 0.69, 95% CI 0.22 to 1.15) compared with placebo. That is a directional harm signal in a specific population, and it belongs in any honest summary of this literature. A treatment with a measurable adverse event burden and no demonstrated benefit for a given indication is not a neutral option for that indication. It carries cost without documented return. Study SnapshotPrimary SourceWilson J, Dobson O, Langcake A, et al. Systematic review and meta-analysis of randomized controlled trialsInstitutionsMatilda Centre, University of Sydney; University of Queensland; Monash University; University of BathSearch WindowJanuary 1, 1980 to May 13, 2025 (Ovid MEDLINE, PsycINFO, Cochrane CENTRAL, Cochrane Database, Embase)Included Trials54 randomized controlled trials, 2,477 participants (69% male, 31% female; median age 33.3 years)Depression FindingAbsence of randomized controlled trial evidence for the treatment of depressionEvidence Quality24 of 54 trials (44%) at high risk of bias; GRADE certainty low for most outcomesSafetyAll-cause adverse events OR 1.75 (95% CI 1.25 to 2.46), NNTH 7; no increase in serious adverse eventsRegistration and FundingPROSPERO CRD42023392718; National Health and Medical Research Council, AustraliaJournalThe Lancet Psychiatry, 2026 Apr;13(4):304-315, online March 16, 2026PMID / DOI41856154 / 10.1016/S2215-0366(26)00015-5Corroborating ReviewBharat C, et al. Psychiatry Research 2026;365:117380. Depression SMD -0.20 (95% CI -0.43 to 0.04). PMID 42617303 How Strong Is This Evidence? As a description of what randomized trials exist, this is strong evidence. Two independent groups, using different inclusion rules and different databases, searched the same forty-five year window and produced compatible answers about depression. A well-conducted systematic search is close to the best available instrument for the question of whether a body of trial evidence exists. As evidence about whether cannabinoids help depression, it is close to silent, and the silence runs in one direction only. Wilson and colleagues found no qualifying trial. Bharat and colleagues found a pooled estimate compatible with no effect, assembled mostly from secondary outcomes and rated at very low certainty. Neither result establishes that cannabis fails in depression. Both establish that the question has not been properly tested. Where This Paper Deserves Skepticism The two reviews are not independent in the way the word usually implies. Several authors appear on both, and both groups draw on the same Australian research infrastructure, the same databases, and overlapping search strategies. Agreement between them is reassuring but is not the same as replication by an unconnected team. The Wilson inclusion rule, requiring the cannabinoid to be the primary treatment for the primary diagnosis, is defensible for regulatory purposes and unrepresentative of clinical practice. Almost no patient takes cannabis instead of an antidepressant with nothing else in the plan. Reading the absence of qualifying depression trials as a verdict on adjunctive use would be reading past what the review measured. Both reviews also carry the standard limits of the underlying literature. The Wilson sample was 69% male with a median age of 33.3 years, which does not match the demographic profile of treated depression in most clinics. Heterogeneity in the Bharat depression pool was 91.6%, which means the individual trials were measuring meaningfully different things. What This Paper Does Not Show Neither review shows that cannabis is ineffective for depression. An absence of trials and a confidence interval that crosses zero are statements about the evidence base, not about the drug. The honest description is that the trials have not been done at adequate quality or scale. Neither review addresses adjunctive use, patient-directed titration, or cannabis used to treat a symptom such as insomnia or pain in a person who also has depression. Those are the situations most patients are actually in, and they sit outside what these designs measured. Neither review tells a clinician what to do with a patient who is already using cannabis and reports that their mood is better. That question has no trial answer at present. How This Fits With the Broader Clinical Conversation The contrast between depression and insomnia inside the same review is the most useful part of this literature. Sleep duration is measurable by device. Tic severity is countable. Grams of cannabis consumed per week is a number the participant can report and the investigator can check. Depression is measured by scales that depend heavily on self-report and expectation, in a trial design where the active drug announces itself through its psychoactive effects. That is not an argument that cannabis works for depression and the instruments are too crude to detect it. It is an argument that the trials required to answer the question would need to be designed with unusual care about blinding, expectation, and outcome selection, and that so far nobody has funded them at the necessary scale. Meanwhile the 2019 Black review, the 2026 Wilson review, and the 2026 Bharat review form an unusually clean sequence. The literature grew. The answer did not change. Dr. Caplan’s Take When a patient tells me cannabis helps their depression, I believe them about their experience. What I cannot do is tell them the trials support it, because the trials do not exist. That is a specific and uncomfortable thing to say out loud, and I think saying it is part of the job. What I have learned over two decades in this work is that the conversation usually gets more productive once the evidence is on the table accurately. Many patients who describe cannabis as helping their depression are describing something more particular when you ask: they are sleeping through the night for the first time in years, or their pain has stopped consuming the whole day, or they are less anxious in the evening. Those are downstream effects with better evidence behind them, and naming them correctly makes the treatment plan easier to build and easier to monitor. The part I find genuinely frustrating is the funding picture. Forty-five years of literature, and not one randomized trial that tested a cannabinoid as a treatment for a depressive disorder well enough to qualify for a systematic review. That is not a scientific verdict. That is a research agenda nobody paid for. Clinical Bottom Line There is no randomized trial evidence that cannabis treats depression as a primary indication, and the broader pooled estimate is compatible with no effect. Patients using cannabis and reporting mood improvement deserve to be taken seriously and asked what specifically changed, because sleep, pain, and anxiety have better evidence behind them and are easier to track. What a Careful Reader Should Take Away Read this as a map of what has been studied, not a verdict on what works. The finding to carry forward is that depression is the largest unfilled hole in cannabinoid psychiatry and that three reviews across seven years agree about it. The finding not to carry forward is any claim that cannabis has been shown to fail in depression, because a trial that was never run cannot fail. Evidence Interpretation Guide Table of Contents - [How to read an empty cell in an evidence table](#How_to_read_an_empty_cell_in_an_evidence_table) - [Cannabis and Depression, Seen From Eight Angles](#Cannabis_and_Depression_Seen_From_Eight_Angles)[Your experience is not the same as the evidence, and both are real](#Your_experience_is_not_the_same_as_the_evidence_and_both_are_real) - [Say the gap out loud](#Say_the_gap_out_loud) - [Overlapping authorship is worth naming](#Overlapping_authorship_is_worth_naming) - [The inclusion rule shapes the answer](#The_inclusion_rule_shapes_the_answer) - [Seven years, same answer](#Seven_years_same_answer) - [What to monitor if a patient continues](#What_to_monitor_if_a_patient_continues) - [What a real depression trial would require](#What_a_real_depression_trial_would_require) - [Program listings and evidence have drifted apart](#Program_listings_and_evidence_have_drifted_apart) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to read an empty cell in an evidence table The Research QuestionDo randomized controlled trials show that cannabinoids treat mental disorders when used as the primary treatment, and what does the depression column contain?The Patient QuestionCannabis seems to help my mood. Is there research behind that, and what should I tell my doctor?The Bottom LineOne 2026 review found no qualifying randomized trial for depression at all. A second found a pooled effect compatible with zero. The question has not been answered because it has not been properly asked. CED Perspective Lens ## Cannabis and Depression, Seen From Eight Angles One empty evidence cell, read through the lenses that matter in clinical practice. Lens OverviewA 54-trial Lancet Psychiatry review of cannabinoids as primary psychiatric treatment reported no randomized evidence for depression. A second 2026 review pooled depression data and found a standardised mean difference of -0.20 with a confidence interval crossing zero. #### Your experience is not the same as the evidence, and both are real If cannabis has made your depression feel more manageable, nothing in these reviews says you are wrong about your own life. What they say is that no properly designed trial has tested whether cannabis treats depression, so nobody can tell you how likely that benefit is, how long it lasts, or who it works for. The most useful thing you can do with that is get specific. Tell your clinician exactly what improved. Sleeping through the night, less pain, less evening anxiety, and feeling less depressed are four different things with four different evidence bases, and only one of them is empty. Lens takeawayDescribe what changed in detail. The specifics are where the better-supported answers live. #### Say the gap out loud Depression sits in a different category from the other indications in this literature. For anxiety and PTSD, trials were run and did not reach significance. For depression, under the Wilson inclusion criteria, no trial qualified at all. Those are different clinical statements and patients can hear the difference. The practical move is to ask what the patient means by depression relief and to document which symptom domain is actually improving. Sleep and pain have better trial support and are easier to monitor over time, and they give you something measurable to titrate against. Lens takeawayDistinguish an untested indication from a tested and negative one. Patients understand the difference. #### Overlapping authorship is worth naming The two 2026 reviews share authors and research infrastructure. Emily Stockings appears on the Wilson paper and on the 2019 Black paper; Louisa Degenhardt and Michael Farrell appear on both the Black and Bharat papers. Agreement across them should not be read as three fully independent confirmations. The stricter concern runs the other way, though. If anything, a tightly connected group applying consistent methods across seven years makes the persistence of the gap harder to dismiss as a search artifact. Lens takeawayShared authorship narrows the independence claim without weakening the underlying finding. #### The inclusion rule shapes the answer Wilson and colleagues required the cannabinoid to be the primary treatment for a primary psychiatric diagnosis. That is the right rule for a regulatory question and the wrong rule for describing practice. Bharat and colleagues relaxed it, allowed symptom-level outcomes, and found depression data, most of it collected as a secondary outcome in trials about something else. Neither approach is wrong. They answer different questions, and a reader who quotes one review’s depression conclusion without naming its inclusion rule is quoting a number stripped of its meaning. Lens takeawayThe inclusion criterion is the finding. Quote it alongside the result. #### Seven years, same answer Black and colleagues searched to April 2018 and concluded that evidence for cannabinoids in depressive disorders was scarce. Wilson searched to May 2025 under stricter rules and found no qualifying trial. Bharat searched to May 2025 under looser rules and found a pooled estimate crossing zero. The literature expanded substantially in that interval, particularly in pain and epilepsy. The depression column did not fill in. Lens takeawayThe gap is stable across three reviews and seven additional years of publication. #### What to monitor if a patient continues For a patient already using cannabis who also carries a depression diagnosis, the reasonable clinical posture is structured observation rather than either endorsement or dismissal. Track sleep, pain, anxiety, and a validated depression measure separately, because they can move in opposite directions. Review interactions, particularly with medications metabolised by cytochrome P450 enzymes, and revisit the plan on a set schedule rather than only when something goes wrong. The adverse event odds ratio of 1.75 from the Wilson review is a reminder that tolerability is not automatic. Lens takeawayMeasure the domains separately and set a review date rather than leaving it open-ended. #### What a real depression trial would require A trial capable of answering this question would need participants recruited for a depressive disorder rather than for pain or multiple sclerosis, a validated primary depression outcome, a blinding strategy that acknowledges THC announces itself, and enough participants to detect a small effect if one exists. It would also need to report expectation and allocation-guessing data, because subjective outcomes in trials where the active arm is psychoactive are vulnerable to exactly that bias. Lens takeawayRecruit for the disorder, measure it directly, and report the blinding data honestly. #### Program listings and evidence have drifted apart Depression appears widely as an accepted reason for medical cannabis certification, either by name or through provider discretion clauses. The evidence supporting that listing is not thin. For the specific claim that cannabis treats a depressive disorder, it is absent. That mismatch is an argument for funding trials rather than for restricting access. Removing an option that patients are already choosing does not generate the data that would settle the question. Lens takeawayThe policy answer to an evidence gap is research funding, not a narrower formulary. Related Reading at CED ClinicContinue exploring the evidence[Cannabinoids for Mental Health and Addiction: What 200 Studies Showed](https://cedclinic.com/cannabinoids-mental-health-addiction-meta-analysis/) Our coverage of the Bharat review, the study that pooled depression data and found an effect compatible with zero. [See the pooled results](https://cedclinic.com/cannabinoids-mental-health-addiction-meta-analysis/)[Cannabinoids in Mental Health Treatment: A Systematic Review of Efficacy and Safety](https://cedclinic.com/cannabinoids-in-mental-health-treatment-a-systematic-review-of-efficacy-and-safety/) The full study record for the Lancet Psychiatry review, including its complete outcome-by-outcome findings. [Read the study record](https://cedclinic.com/cannabinoids-in-mental-health-treatment-a-systematic-review-of-efficacy-and-safety/)[The New Science of Cannabis and Sleep](https://cedclinic.com/the-new-science-of-cannabis-and-sleep/) Sleep was one of the clearest positive signals in the same review, and it is often what patients mean when they say their mood improved. [Explore the sleep evidence](https://cedclinic.com/the-new-science-of-cannabis-and-sleep/) Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) ## Frequently Asked Questions Does cannabis treat depression? No randomized trial has tested it properly. A 2026 systematic review in The Lancet Psychiatry searched forty-five years of literature for trials using cannabinoids as the primary treatment for a diagnosed mental disorder and reported an outright absence of randomized controlled trial evidence for depression. A separate 2026 review that allowed broader inclusion pooled depression symptom data and found a standardised mean difference of -0.20, with a confidence interval that crossed zero. Why is there no trial evidence for cannabis and depression? The trials were not run at sufficient quality or scale. Cannabis research faced decades of regulatory barriers, and most cannabinoid trials that measured depression scores did so as a secondary outcome in people recruited for another condition, such as chronic pain or multiple sclerosis. Those secondary measurements cannot answer whether cannabis treats a depressive disorder in people who have one. What did the 2026 Lancet Psychiatry review find overall? It included 54 randomized trials covering 2,477 participants. Cannabidiol combined with THC reduced cannabis withdrawal symptoms and weekly cannabis use in cannabis use disorder, and reduced tic severity in Tourette’s syndrome. Any cannabinoid increased sleep time in insomnia, and autistic traits decreased in autism spectrum disorder. There were no significant effects for anxiety, anorexia nervosa, psychotic disorders, PTSD, or opioid use disorder, and no qualifying evidence at all for depression. Does a null result mean cannabis makes depression worse? No. A confidence interval crossing zero means the data are compatible with benefit, harm, or nothing, and cannot distinguish between them. The Bharat review’s depression estimate ran from -0.43 to 0.04, which includes a small benefit at one end and no effect at the other. An absence of qualifying trials, as in the Wilson review, says nothing at all about direction. Should I stop using cannabis if I have depression? That decision belongs with your treating clinician and should not be made from a headline. These reviews describe what the trial literature contains, not what is happening in your body. The useful step is to describe precisely what improved when you started, because sleep, pain, and anxiety have better evidence behind them and are easier to track and adjust than a global sense of mood. Is cannabis safe to use alongside antidepressants? It requires review rather than assumption. Cannabinoids are metabolised through cytochrome P450 enzymes and can interact with medications cleared by the same pathways, including several antidepressants. The 2026 Lancet Psychiatry review found higher odds of all-cause adverse events with cannabinoids compared with control, at an odds ratio of 1.75, with a number needed to treat to harm of 7, though serious adverse events did not increase. What does GRADE certainty low actually mean? GRADE is a standard framework for rating how much confidence an estimate deserves, running from very low to high. A rating of low means there is a real possibility that the true effect differs substantially from what the study reported. The Lancet Psychiatry review rated certainty as low for most outcomes, and the broader Psychiatry Research review rated its evidence predominantly very low, which is the weakest rating available. Has this gap been reported before? Yes, repeatedly. A 2019 systematic review in The Lancet Psychiatry by Black and colleagues searched to April 2018, included 83 studies, and concluded that evidence for cannabinoids improving depressive disorders was scarce. Two independent 2026 reviews searching to May 2025 reached compatible conclusions. Three reviews across seven years and a substantially larger literature have not changed the answer. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).